Masitinib治疗阿尔茨海默症的AB09004研究的中期分析结果

2019-06-27 Allan MedSci原创

AB09004研究是一项国际性、随机、安慰剂对照的III期研究,正在评估Masitinib治疗轻度至中度阿尔茨海默症。该研究评估了Masitinib联合胆碱酯酶抑制剂和/或美金刚的有效性和安全性。

AB09004研究是一项国际性、随机、安慰剂对照的III期研究,正在评估Masitinib治疗轻度至中度阿尔茨海默症。该研究评估了Masitinib联合胆碱酯酶抑制剂和/或美金刚的有效性和安全性。主要终点是ADAS-Cog的变化,次要终点是ADCS-ADL的变化。该研究招募了720例患者。

Masitinib在阿尔茨海默症中的潜在治疗益处可能与的两种Masitinib的作用机制有关:1)血脑屏障(BBB)通透性的调节; 2)蛋白激酶Fyn的抑制(Fyn参与淀粉样蛋白信号传导和tau磷酸化)。


原始出处:

http://www.firstwordpharma.com/node/1649806#axzz5s0nRyue8

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816920, encodeId=7cde1816920f6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Oct 08 23:39:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958301, encodeId=b92f1958301c7, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Sep 19 01:39:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910521, encodeId=bc7c19105210b, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Apr 17 02:39:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077458, encodeId=ebb220e745825, content=<a href='/topic/show?id=1b331e115e' target=_blank style='color:#2F92EE;'>#AB09004研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1711, encryptionId=1b331e115e, topicName=AB09004研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sat Feb 15 20:39:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817943, encodeId=0465181e9436e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 19 03:39:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470297, encodeId=ea7f14e0297c8, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 02:39:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1816920, encodeId=7cde1816920f6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Oct 08 23:39:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958301, encodeId=b92f1958301c7, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Sep 19 01:39:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910521, encodeId=bc7c19105210b, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Apr 17 02:39:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077458, encodeId=ebb220e745825, content=<a href='/topic/show?id=1b331e115e' target=_blank style='color:#2F92EE;'>#AB09004研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1711, encryptionId=1b331e115e, topicName=AB09004研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sat Feb 15 20:39:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817943, encodeId=0465181e9436e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 19 03:39:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470297, encodeId=ea7f14e0297c8, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 02:39:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
    2019-09-19 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1816920, encodeId=7cde1816920f6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Oct 08 23:39:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958301, encodeId=b92f1958301c7, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Sep 19 01:39:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910521, encodeId=bc7c19105210b, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Apr 17 02:39:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077458, encodeId=ebb220e745825, content=<a href='/topic/show?id=1b331e115e' target=_blank style='color:#2F92EE;'>#AB09004研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1711, encryptionId=1b331e115e, topicName=AB09004研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sat Feb 15 20:39:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817943, encodeId=0465181e9436e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 19 03:39:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470297, encodeId=ea7f14e0297c8, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 02:39:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
    2020-04-17 zhanglin3079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1816920, encodeId=7cde1816920f6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Oct 08 23:39:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958301, encodeId=b92f1958301c7, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Sep 19 01:39:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910521, encodeId=bc7c19105210b, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Apr 17 02:39:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077458, encodeId=ebb220e745825, content=<a href='/topic/show?id=1b331e115e' target=_blank style='color:#2F92EE;'>#AB09004研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1711, encryptionId=1b331e115e, topicName=AB09004研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sat Feb 15 20:39:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817943, encodeId=0465181e9436e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 19 03:39:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470297, encodeId=ea7f14e0297c8, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 02:39:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1816920, encodeId=7cde1816920f6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Oct 08 23:39:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958301, encodeId=b92f1958301c7, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Sep 19 01:39:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910521, encodeId=bc7c19105210b, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Apr 17 02:39:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077458, encodeId=ebb220e745825, content=<a href='/topic/show?id=1b331e115e' target=_blank style='color:#2F92EE;'>#AB09004研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1711, encryptionId=1b331e115e, topicName=AB09004研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sat Feb 15 20:39:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817943, encodeId=0465181e9436e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 19 03:39:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470297, encodeId=ea7f14e0297c8, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 02:39:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1816920, encodeId=7cde1816920f6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Oct 08 23:39:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958301, encodeId=b92f1958301c7, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Sep 19 01:39:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910521, encodeId=bc7c19105210b, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Apr 17 02:39:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077458, encodeId=ebb220e745825, content=<a href='/topic/show?id=1b331e115e' target=_blank style='color:#2F92EE;'>#AB09004研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1711, encryptionId=1b331e115e, topicName=AB09004研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sat Feb 15 20:39:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817943, encodeId=0465181e9436e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 19 03:39:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470297, encodeId=ea7f14e0297c8, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jun 29 02:39:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]

相关资讯

第14届阿尔茨海默症和帕金森国际会议:Aptinyx将介绍NYX-458的临床前数据

Aptinyx是一家临床阶段的生物制药公司,开发用于治疗大脑和神经系统疾病的变革疗法,近日宣布即将在第14届阿尔茨海默症和帕金森国际会议上发表演讲,重点介绍其新型NMDA受体调节剂NYX-458的临床前数据

植入记忆法:或为阿尔茨海默病患者寻回记忆

阿尔茨海默症(Alzheimer)俗称老年痴呆症。其病理为:淀粉样蛋白斑在大脑中累积从而阻碍脑细胞交流信息。患者通常会丧失情节记忆(episodic memory),如记不得刚刚把车停哪儿了、钥匙放哪儿了。遗忘这些日常场景信息无疑给老年人的生活带来极大不便。所幸,据英国《每日电讯报》(The Telegraph)报道,美国有试验性研究表明阿尔茨海默病患者有望恢复记忆,重新记起亲人以及回家的路!“植

2018年 阿尔茨海默病领域的10大重磅交易

全球大约有几千万名的阿尔茨海默病患者。阿尔茨海默病患者的两大重要病理特征为大脑中的淀粉样蛋白(Aβ)沉积和神经细胞中tau蛋白聚集导致的神经原纤维缠结。

第14届阿尔茨海默症和帕金森国际会议:Eisai将公布其一系列在研药物的临床试验结果

Eisai公司近日宣布,将于3月26日举行的第14届阿尔茨海默症和帕金森国际会议上公布其一系列在研药物的临床试验结果:BAN2401,一种抗淀粉样蛋白β(Aβ)初原纤维抗体,正在进行III期试验;elenbecestat,一种口服选择性BACE1抑制剂,目前正在进行两项III期研究(MISSION AD1 / 2)。

“绕开”致病蛋白!预防老年痴呆症的基因疗法试验即将启动

将来有一天,APOE4患者去看医生,一次性注射APOE2,或许就能预防阿尔茨海默症。

由于毒理学发现,Allergan/Sosei公司将延迟阿尔茨海默症新药HTL0018318的临床开发

由于在非人类灵长类动物的研究中意外发现的毒理作用,Allergan和Sosei自愿暂停HTL0018318的临床开发工作。